Journal
JOURNAL OF IMMUNOLOGY
Volume 165, Issue 10, Pages 5552-5557Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.165.10.5552
Keywords
-
Categories
Funding
- NCI NIH HHS [CA66570] Funding Source: Medline
- NIAID NIH HHS [AI28847, AI07260] Funding Source: Medline
Ask authors/readers for more resources
The imidazoquinoline R-848, originally identified as a highly effective antiviral agent, has recently been shown to be capable of potent B lymphocyte activation. The B cell-activating properties of R-848 are strikingly similar to the effects of the CD40 ligand CD154, The present study demonstrates that this similarity extends to the intracellular signaling pathways triggered by the compound, although both overlapping and distinct mechanisms of signaling were seen. Like CD40 ligation, R-848 stimulated activation of the stress-activated protein kinases c-Jun kinase and p38 and activated the NF-kappaB family of transcription factors. Both R-848 and CD40-mediated B cell differentiation were dependent upon NF-kappaB activation, although the relative importance of individual NF-kappaB family members appeared to differ between R-848- and CD40-mediated signals, Both signals were partially dependent upon induction of TNF-alpha and IL-6, and the cytoplasmic adaptor molecule TNF receptor-associated factor 2 is involved in both R-848- and CD40-mediated differentiation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available